Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
NeoCOAST-2 Phase II Study in Resectable Early-stage NSCLC
2021-003369-37Phase 2Active
- Sponsor
- AstraZeneca
- Start
- Feb 2022
- Modality
- PD-1/PD-L1 Inhibitors → Immune Checkpoint Inhibitors → Monoclonal Antibodies → Antibody-Based Therapeutics, Vaccines & Immunotherapeutics, Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial of durvalumab, oleclumab and monalizumab in non-small cell lung cancer (NSCLC), sponsored by AstraZeneca. Primary endpoint: Pathologic complete response (pCR). Started Feb 2022; status: active.
02
Drugs
durvalumaboleclumabmonalizumab
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on 2021-003369-37.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2021-003369-37.